Bai Shilei, Yang Pinghua, Wei Yanping, Wang Jie, Lu Caixia, Xia Yong, Si Anfeng, Zhang Baohua, Shen Feng, Tan Yexiong, Wang Kui
Department of Hepatic Surgery II, The Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Department of Biliary Surgery IV, The Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Front Oncol. 2023 Apr 19;13:1166327. doi: 10.3389/fonc.2023.1166327. eCollection 2023.
The prediction models of postoperative survival for hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) with microvascular invasion (MVI) have not been well established. The study objective was the development of nomograms to predict disease recurrence and overall survival (OS) in these patients.
Data were obtained from 1046 HBV-related MVI-positive HCC patients who had undergone curative resection from January 2014 to December 2017. The study was approved by the Eastern Hepatobiliary Surgery Hospital and Jinling Hospital ethics committee, and patients provided informed consent for the use of their data. Nomograms for recurrence and OS were created by Cox regression model in the training cohort (n=530). The modes were verified in an internal validation cohort (n= 265) and an external validation cohort (n= 251).
The nomograms of recurrence and OS based on preoperative serological indicators (HBV-DNA, neutrophil-lymphocyte ratio, a-fetoprotein), tumor clinicopathologic features (diameter, number), surgical margin and postoperative adjuvant TACE achieved high C-indexes of 0.722 (95% confidence interval [CI], 0.711-0.732) and 0.759 (95% CI, 0.747-0.771) in the training cohort, respectively, which were significantly higher than conventional HCC staging systems (BCLC, CNLC, HKLC).The nomograms were validated in the internal validation cohort (0.747 for recurrence, 0.758 for OS) and external validation cohort(0.719 for recurrence, 0.714 for OS) had well-fitted calibration curves. Our nomograms accurately stratified patients with HBV-HCC with MVI into low-, intermediate- and high-risk groups of postsurgical recurrence and mortality. Prediction models for recurrence-free survival (https://baishileiehbh.shinyapps.io/HBV-MVI-HCC-RFS/) and OS (https://baishileiehbh.shinyapps.io/HBV-MVI-HCC-OS/) were constructed.
The two nomograms showed good predictive performance and accurately distinguished different recurrence and OS by the nomograms scores for HBV-HCC patients with MVI after resection.
乙型肝炎病毒相关肝细胞癌(HBV-HCC)伴微血管侵犯(MVI)患者术后生存的预测模型尚未完全建立。本研究的目的是开发列线图,以预测这些患者的疾病复发和总生存期(OS)。
收集2014年1月至2017年12月期间接受根治性切除术的1046例HBV相关MVI阳性HCC患者的数据。本研究经东方肝胆外科医院和金陵医院伦理委员会批准,患者均签署了使用其数据的知情同意书。通过Cox回归模型在训练队列(n=530)中创建复发和OS的列线图。模型在内部验证队列(n=265)和外部验证队列(n=251)中进行验证。
基于术前血清学指标(HBV-DNA、中性粒细胞与淋巴细胞比值、甲胎蛋白)、肿瘤临床病理特征(直径、数量)、手术切缘和术后辅助经动脉化疗栓塞术构建的复发和OS列线图,在训练队列中的C指数分别达到0.722(95%置信区间[CI],0.711-0.732)和0.759(95%CI,0.747-0.771),显著高于传统的HCC分期系统(BCLC、CNLC、HKLC)。列线图在内部验证队列(复发为0.747,OS为0.758)和外部验证队列(复发为0.719,OS为0.714)中得到验证,校准曲线拟合良好。我们的列线图准确地将伴有MVI的HBV-HCC患者分为术后复发和死亡的低、中、高风险组。构建了无复发生存期(https://baishileiehbh.shinyapps.io/HBV-MVI-HCC-RFS/)和OS(https://baishileiehbh.shinyapps.io/HBV-MVI-HCC-OS/)的预测模型。
这两个列线图显示出良好的预测性能,通过列线图评分能够准确区分切除术后伴有MVI的HBV-HCC患者的不同复发情况和OS。